{"id":30877,"date":"2025-01-24T15:38:36","date_gmt":"2025-01-24T10:08:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30877"},"modified":"2025-10-09T17:05:02","modified_gmt":"2025-10-09T11:35:02","slug":"mergers-and-acquisitions-from-jp-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference","title":{"rendered":"Pharma & Biotech Reshaped: Key Mergers and Acquisitions from J.P. Morgan 2025"},"content":{"rendered":"\n

The 2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry\u2019s largest consolidation wave in recent years. <\/p>\n\n\n\n

The M&A rebound<\/strong> in the healthcare sector has been years in the making, as pharma giants like J&J<\/strong>, GSK<\/strong>, and others face looming patent cliffs<\/strong>, threatening billions in revenue. Companies are under increasing pressure to refill their pipelines<\/strong>. This urgency has sparked a surge in both early and late-stage asset acquisitions<\/strong>. In the coming year, we can expect continued momentum in deal-making, with larger financing sizes linked to milestone-based acquisitions that help mitigate development risks.<\/p>\n\n\n\n

At the forefront, Johnson & Johnson made a bold move with a $14.6 billion<\/strong> acquisition of neuropsychiatric biotech Intra-Cellular Therapies, the biggest deal of the conference since 2018. This landmark transaction underscores the growing focus on mental health treatments, signaling a shift in J&J’s strategic vision. <\/p>\n\n\n\n

Not to be outdone, GSK made waves with its $1 billion acquisition of IDRx, expanding its oncology pipeline and reaffirming its commitment to high-impact, innovative therapies.<\/p>\n\n\n\n

Further exemplified by Eli Lilly\u2019s<\/strong> strategic purchase of Scorpion Therapeutics<\/strong>, securing innovative therapies poised to make a significant impact on patient care.<\/p>\n\n\n\n

<\/span><\/p>\n

\n<\/colgroup>\n\n\n\n\n\n\n\n
\n

Company 1<\/span><\/p>\n<\/td>\n

\n

Company 2<\/span><\/p>\n<\/td>\n

\n

Deal Type<\/span><\/p>\n<\/td>\n

\n

Deal Value<\/span><\/p>\n<\/td>\n

\n

Asset<\/span><\/p>\n<\/td>\n

\n

Significance<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Johnson & Johnson<\/span><\/p>\n<\/td>\n

\n

Intra-Cellular Therapies<\/span><\/p>\n<\/td>\n

\n

Acquisition<\/span><\/p>\n<\/td>\n

\n

$14.6 billion<\/span><\/p>\n<\/td>\n

\n

CAPLYTA along with other pipeline Neurology portfolio<\/span><\/p>\n<\/td>\n

\n

The deal grants J&J access to Caplyta, a potential blockbuster for bipolar disorder and schizophrenia, along with a promising pipeline of neuropsychiatric therapies<\/span>.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Gilead<\/span><\/p>\n<\/td>\n

\n

LEO Pharma<\/span><\/p>\n<\/td>\n

\n

Partnership<\/span><\/p>\n<\/td>\n

\n

$1.7 Billion<\/span><\/p>\n<\/td>\n

\n

oral STAT6 program for the potential treatment of patients with inflammatory diseases<\/span><\/p>\n<\/td>\n

\n

Gilead is strategically positioning itself to maintain its leadership in biopharmaceuticals while expanding into a major Inflammatory condition Atopic dermatitis, COPD, and Asthma<\/span><\/p>\n

<\/td>\n<\/tr>\n

\n

Eli Lilly<\/span><\/p>\n<\/td>\n

\n

Scorpion Therapeutics<\/span><\/p>\n<\/td>\n

\n

Acquisition<\/span><\/p>\n<\/td>\n

\n

$2.5 billion<\/span><\/p>\n<\/td>\n

\n

PI3Kα inhibitor program STX-478<\/span><\/p>\n<\/td>\n

\n

After taking a hit in the space with the failure of LOXO-783, Lilly attempts to come back with a potential best in class PI3Kα<\/span><\/p>\n

The deal puts Eli Lilly back in the game against its peers Novartis and Roche which successfully launched their PI3K inhibitors Piqray and Itovebi respectively <\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Abbvie<\/span><\/p>\n<\/td>\n

\n

Simcere Zaiming<\/span><\/p>\n<\/td>\n

\n

Licensing Agreement<\/span><\/p>\n<\/td>\n

\n

$1 billion<\/span><\/p>\n<\/td>\n

\n

SIM0500<\/span><\/p>\n<\/td>\n

\n

Following the stride of ~20 deals in 2024, AbbVie is focused on early-stage opportunities<\/span><\/p>\n

However, after cutting loose with Harpoon Therapeutics in 2023 on anti-BCMA T-cell engager HPN217, it will be interesting to watch out how this deal on another tri-specific antibody will roll out. SIMO500 is under development in US and China for R\/R multiple myeloma patients  <\/span><\/p>\n<\/td>\n<\/tr>\n

\n

SpringWorks<\/span><\/p>\n<\/td>\n

\n

Rappta Therapeutics<\/span><\/p>\n<\/td>\n

\n

Licensing Agreement<\/span><\/p>\n<\/td>\n

\n

$13 million<\/span><\/p>\n<\/td>\n

\n

RPT04402<\/span><\/p>\n<\/td>\n

\n

Adding advance novel cancer “therapeutics, capitalizing on the growing interest in protein degradation technologies for overcoming treatment resistance in oncology<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

The deals announced this week offer a clear picture of shifting industry priorities. J&J<\/strong>, facing rising competition for its immunology standout STELARA<\/strong>, has refocused on neuropsychiatry<\/strong>, building on recent success with Spravato<\/strong>. Meanwhile, GSK\u2019s near-term patent expiration for the HIV drug dolutegravir<\/strong> has led the company to double down on oncology<\/strong>, a field with stable growth potential.<\/p>\n\n\n\n

Amidst these strategic maneuvers, 2024<\/strong> was a year marked by economic uncertainties<\/strong>, regulatory challenges<\/strong>, and intensifying antitrust scrutiny<\/strong>, complicating the healthcare M&A landscape<\/strong>. With a new Trump administration<\/strong> potentially altering the political and regulatory climate, some stakeholders might find opportunities, while others face new hurdles. Companies that proactively address these challenges are likely to be better positioned for success in an uncertain market.<\/p>\n\n\n\n

Several key developments are expected to impact healthcare and life sciences companies in the coming year:<\/p>\n\n\n\n

    \n
  • FDA Under the New Trump Administration:<\/strong> Regulatory changes will influence the approval processes for new drugs and treatments<\/li>\n\n\n\n
  • Changes to ACA<\/strong>: Revisions to the Affordable Care Act could reshape healthcare access and insurance structures.  <\/li>\n\n\n\n
  • Inflation Reduction Act<\/strong>: Many industry stakeholders are eager to see reforms, such as a repeal of the \u201cpill penalty,\u201d a provision in the IRA that reduces the period of exclusivity for small molecule drugs to 9 years, while biologic drugs get 13 years.<\/li>\n\n\n\n
  • Heightened Antitrust Scrutiny<\/strong>: Increased enforcement could complicate healthcare M&A activities.  <\/li>\n\n\n\n
  • State Focus on Healthcare Transaction Oversight<\/strong>: Local governments may impose stricter controls on mergers and acquisitions.  <\/li>\n\n\n\n
  • Cybersecurity Risks<\/strong>: Data breaches continue to pose a threat to healthcare companies, impacting both operations and dealmaking.  <\/li>\n\n\n\n
  • Regulatory Oversight of AI<\/strong>: Growing scrutiny of artificial intelligence in healthcare could introduce new challenges for tech-driven innovations.  <\/li>\n\n\n\n
  • Healthcare\u2019s Patient-Centric Future<\/strong>: The shift towards patient-centered care will drive changes in treatment models and industry dynamics.  <\/li>\n\n\n\n
  • Political Pressure on Healthcare Companies<\/strong>: Heightened political focus could lead to greater oversight and influence decisions within companies.  <\/li>\n\n\n\n
  • False Claims Act<\/strong>: Legal risks related to healthcare fraud may increase with stricter enforcement.  <\/li>\n\n\n\n
  • SCOTUS Opinions to Watch<\/strong>: Potential Supreme Court rulings could reshape the regulatory landscape in 2025.<\/li>\n<\/ul>\n\n\n\n

    Depending on policy developments, 2025 could either offer growth opportunities<\/strong> for healthcare companies or introduce new risks and challenges<\/strong> that will reshape the sector. Stakeholders who remain agile and address these evolving dynamics will be best positioned to navigate the complexities of the market.<\/p>\n\n\n\n

    FAQs<\/h2>\n\n\n\n
    Which major pharmaceutical companies were involved in significant M&A deals at the 2025 J.P. Morgan Healthcare Conference?<\/strong><\/strong>

    Key players such as Johnson & Johnson, Bristol-Myers Squibb, and Pfizer were actively engaged in notable acquisitions, aiming to bolster their oncology and CNS (central nervous system) portfolios.<\/p> <\/div>

    How are cell and gene therapies influencing M&A strategies?<\/strong><\/strong>

    The accelerating progress in cell and gene therapies is driving M&A strategies, with companies seeking to integrate innovative technologies and expand their treatment offerings in complex and previously untreatable conditions.<\/p> <\/div>

    What therapeutic areas are attracting the most M&A interest?<\/strong><\/strong>

    Oncology and central nervous system disorders are at the forefront, with companies targeting acquisitions that enhance their capabilities in these high-demand therapeutic areas.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"

    The 2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry\u2019s largest consolidation wave in recent years.  The M&A rebound in the healthcare sector has been years in the making, as pharma giants like J&J, GSK, and others face looming patent cliffs, threatening billions in revenue. Companies are under increasing […]<\/p>\n","protected":false},"author":14,"featured_media":30879,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[21664,21663,683,21722],"industry":[17225],"therapeutic_areas":[17227,17245],"class_list":["post-30877","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-jp-morgan","tag-jp-morgan-healthcare-conference","tag-mergers-and-acquisitions","tag-mergers-and-acquisitions-in-the-healthcare","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nMergers and Acquisitions from J.P. Morgan 2025<\/title>\n<meta name=\"description\" content=\"2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry\u2019s largest consolidation wave in recent years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mergers and Acquisitions from J.P. Morgan 2025\" \/>\n<meta property=\"og:description\" content=\"2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry\u2019s largest consolidation wave in recent years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-24T10:08:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-09T11:35:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/24153159\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mergers and Acquisitions from J.P. Morgan 2025","description":"2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry\u2019s largest consolidation wave in recent years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference","og_locale":"en_US","og_type":"article","og_title":"Mergers and Acquisitions from J.P. Morgan 2025","og_description":"2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry\u2019s largest consolidation wave in recent years.","og_url":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-01-24T10:08:36+00:00","article_modified_time":"2025-10-09T11:35:02+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/24153159\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference","url":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference","name":"Mergers and Acquisitions from J.P. Morgan 2025","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/24153159\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference.png","datePublished":"2025-01-24T10:08:36+00:00","dateModified":"2025-10-09T11:35:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry\u2019s largest consolidation wave in recent years.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009666548"},{"@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009673110"},{"@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009690832"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/24153159\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/24153159\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference.png","width":466,"height":284,"caption":"mergers-and-acquisitions-from-jp-morgan-healthcare-conference"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009666548","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009666548","name":"Which major pharmaceutical companies were involved in significant M&A deals at the 2025 J.P. Morgan Healthcare Conference?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key players such as Johnson & Johnson, Bristol-Myers Squibb, and Pfizer were actively engaged in notable acquisitions, aiming to bolster their oncology and CNS (central nervous system) portfolios.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009673110","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009673110","name":"How are cell and gene therapies influencing M&A strategies?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The accelerating progress in cell and gene therapies is driving M&A strategies, with companies seeking to integrate innovative technologies and expand their treatment offerings in complex and previously untreatable conditions.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009690832","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference#faq-question-1760009690832","name":"What therapeutic areas are attracting the most M&A interest?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Oncology and central nervous system disorders are at the forefront, with companies targeting acquisitions that enhance their capabilities in these high-demand therapeutic areas.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/24153159\/mergers-and-acquisitions-from-jp-morgan-healthcare-conference-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">JP Morgan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">JP Morgan Healthcare Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Mergers and Acquisitions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Mergers and Acquisitions in the Healthcare<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">JP Morgan<\/span>","<span class=\"advgb-post-tax-term\">JP Morgan Healthcare Conference<\/span>","<span class=\"advgb-post-tax-term\">Mergers and Acquisitions<\/span>","<span class=\"advgb-post-tax-term\">Mergers and Acquisitions in the Healthcare<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Jan 24, 2025","modified":"Updated on Oct 9, 2025"},"absolute_dates_time":{"created":"Posted on Jan 24, 2025 3:38 pm","modified":"Updated on Oct 9, 2025 5:05 pm"},"featured_img_caption":"mergers-and-acquisitions-from-jp-morgan-healthcare-conference","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30877"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30877\/revisions"}],"predecessor-version":[{"id":33640,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30877\/revisions\/33640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30879"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30877"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30877"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}